We provide proven modeling & simulation, regulatory science, and scientific value assessment software and services to help our clients reduce clinical trial burden, accelerate regulatory approval and increase patient access to medicines.
For more information, visit www.certara.com.
For more information, visit www.certara.com.
Location: France, Ile-de-France, Paris
Employees: 501-1000
Phone: +1 609-716-7900
Founded date: 2008
Investors 5
| Date | Name | Website |
| - | Arsenal Ca... | arsenalcap... |
| - | Vector Cap... | vectorcapi... |
| 06.10.2021 | Mubadala C... | mubadala.c... |
| - | EQT | eqtgroup.c... |
| - | Solstice C... | solcap.com |
Mentions in press and media 23
| Date | Title | Description |
| 02.09.2025 | AI-driven drug discovery picks up as FDA pushes to reduce animal testing | Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near future. Within the next three to five years, using ... |
| 08.07.2025 | Certara Expands Partnership with Merck to Streamline Drug Development Data Standards | What You Should Know: – Certara, a global leader in model-informed drug development, today announced an expanded collaboration with Merck, known as MSD outside of the United States and Canada. – The strategic agreement will see Merck increa... |
| 17.01.2025 | Recent Digital Health Executive Hires and Promotions: Medidata Expands Team, CareRev, Philips, Eko Health, Others | AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO. Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shi... |
| 15.08.2024 | Certara Launches Phoenix™ Version 8.5 Drug Development Software | RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry's gold standard in p... |
| 10.05.2024 | Health | Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge | The FDA conditionally approved sotorasib but required Amgen to conduct a study comparing the labeled dosage of 960 mg with a dosage of 240 mg. The trial, published in November, showed that the 960-mg dose may have given patients a month mor... |
| 15.12.2023 | Certara Acquires Applied BioMath to Expand Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing | Certara, Inc. announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D). Together, Certara ... |
| 21.11.2023 | Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development | Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies PRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in... |
| 13.03.2023 | AI Coming to Certara’s D360 Scientific Informatics Software | New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. Certara, a global leader in biosimulation, is adding deep learning capabilities to D360, a... |
| 21.12.2021 | Certara Announces FDA Renewal and Expansion of Certara's Biosimulation Software for Reviewing Regulatory Submissions | PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprieta... |
| 10.11.2021 | Certara Reports Third Quarter 2021 Financial Results | PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2021. Highlights: Revenue was $73.9 million, compar... |
Show more